Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA
First author:Anxin Wang,Jie Xu
Corresponding author:Yilong Wang
2018-08-08
Journal:Neurology
Publication type: Original Contributions
IF(IF): 9.91
PMID: 30089614 Link To Pubmed Full text Download
The oxidized low-density lipoprotein (oxLDL), which is the major modified form of low-density lipoprotein (LDL), has been identified as an important contributing factor to atherosclerotic lesions. It has been reported that there was a significant correlation between plaque and circulating oxLDL levels. In apparently healthy individuals, the levels of circulating oxLDL were indicative of levels of inflammatory response and oxidative stress in systemic arteries. In patients with acute coronary artery diseases, the elevated levels of circulating oxLDL were directly related to the release of modified LDL from ruptured plaques. Some studies have reported the predictive value of circulating oxLDL for future cardiac events in the general population, as well as in patients with prior cardiovascular diseases (CVDs). OxLDL level was also increased in patients with acute ischemic stroke6 and was related to poor functional outcome after stroke. However, its role to predict a new vascular event in patients who already had a stroke remains unclear. It is well known that patients with minor stroke or TIA are at high immediate risk for recurrent stroke.8 Approximately 10% to 20% of these patients would have a new stroke within the first 3 months.8,9 In the present study, we sought to investigate whether circulating oxLDL could predict recurrent stroke using data from the cohort of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial.
In the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial, baseline oxLDL levels were blindly measured in plasma with the 4E6 antibody in the core laboratory. The primary outcome was any stroke within 90 days. The secondary outcomes included any stroke within 1 year and ischemic stroke and combined vascular events within 90 days and 1 year. The associations of oxLDL with recurrent stroke were analyzed by Cox proportional hazards.
Elevated oxLDL levels can independently predict recurrent stroke in patients with minor stroke or TIA.
Among 3,019 patients included in this study, the median (interquartile range) of oxLDL was 13.96 (6.65–28.81) μg/dL. After adjustment for conventional confounding factors, patients in the highest oxLDL quartile (≥28.81 μg/dL) had a higher risk of recurrent stroke within 90 days (hazard ratio 1.43, 95% confidence interval 1.03–1.98) compared to those in the lowest oxLDL quartile (<6.65 μg/dL). Similar results were found for secondary outcomes. We also found a J-shaped association between oxLDL and risk of each outcome. There were no significant interactions between oxLDL and low-density lipoprotein and use of dual antiplatelet, antihypertensive, antidiabetic, and statins agents.